ANTWERP PHARMACIES has a registered holding activity and consists mainly of financial fixed assets; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €4.32M and a net result of €2.22M. Equity is growing by ~26.1% per year across the filed fiscal years. Its solvency ranks better than 20% of 2381 sector peers (fiscal year 2025). The company has been active since 2018 and the Belgian State Gazette contains no insolvency or warning signals.
Checked score
Outside the general model
Holding: general score not applicable
The company has a registered holding activity and financial fixed assets account for more than half of its assets. The general operating-company model is unsuitable for this profile, so we show no financial axes either. Filed figures remain available.
Credit advice for your own amount and term
Signals
Three signals. The signal on the left, the evidence on the right.
○neutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 10-07-2026, 21 days ahead of the deadline.
NBB · 7 filingsDeviation from the deadline
2025
21 d early
2024
65 d early
2023
55 d early
2022
54 d early
2021
26 d early
2020
60 d early
2019
39 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
18-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, full schema
Turnover
€1.20M
EBIT margin
54.8%
Net result
€2.22M▲ 850%
2024 · €234k
2019: €249k
2020: €530k
2021: €497k
2022: €372k
2023: €193k
2024: €234k
2019 → 2025
Working capital
€-3.22M▲ 23.4%
2024 · €-4.20M
2019: €-1.37M
2020: €-1.47M
2021: €-2.15M
2022: €-2.27M
2023: €-3.35M
2024: €-4.20M
2019 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Turnover€1.20M
Equity€1.30M-€1.67M▲ 28.7%€1.86M▲ 11.6%€2.10M▲ 12.6%€4.32M▲ 106%
Operating result€743k-€558k▼ 24.9%€432k▼ 22.6%€616k▲ 42.7%€655k▲ 6.2%
Net result€497k-€372k▼ 25.1%€193k▼ 48.0%€234k▲ 21.0%€2.22M▲ 850%
Result per fiscal year
Operating resultNet result
After the dip in 2023 the operating result has climbed two years in a row; 2025 is 6% above 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €16.91M
Fixed assets
€15.91M▲ 3.4%
Current assets
€994k▲ 0.8%
Equity and liabilities €16.91M
Equity
€4.32M▲ 106%
Debt
€12.59M▼ 11.9%
The debt ratio falls from 87.2% to 74.5%. Equity is higher and debt is lower.
Key figures and ratios
Solvency
25.5%▲
2024 · 12.8%
ROE
51.5%▲
2024 · 11.2%
ROA
13.1%▲
2024 · 1.4%
Debt
€12.59M▼
2024 · €14.29M
Debt ≤ 1 year
€4.21M▼
2024 · €5.19M
Debt > 1 year
€8.36M▼
2024 · €9.08M
Income taxes
€66k▼
2024 · €76k
Staff costs
€287k▲
2024 · €208k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€16.39M€16.91M▲
Fixed assets21/28€15.40M€15.91M▲
Financial fixed assets28€15.40M€15.91M▲
Affiliated companies280/1-€15.91M
Participating interests280-€15.91M
Current assets29/58€986k€994k▲
Stocks and contracts in progress3-€0
Amounts receivable within one year40/41€923k€669k▼
Trade receivables40-€12k
Other amounts receivable41€923k€657k▼
Cash at bank and in hand54/58€63k€318k▲
Deferred charges and accrued income490/1-€8k
Equity and liabilities
Total equity and liabilities10/49€16.39M€16.91M▲
Equity10/15€2.10M€4.32M▲
Contributions10/11€19k€19k=
Reserves13€2.08M€4.30M▲
Non-distributable reserves130/1€2k€2k=
Reserves not available under the articles1311€2k€2k=
Distributable reserves133€2.07M€4.30M▲
Amounts payable17/49€14.29M€12.59M▼
Amounts payable after more than one year17€9.08M€8.36M▼
Financial debts170/4€9.08M€8.36M▼
Subordinated loans170-€1.51M
Credit institutions173-€6.85M
Amounts payable within one year42/48€5.19M€4.21M▼
Current portion of amounts payable after more than one year42€876k€807k▼
Financial debts43€10k€29k▲
Credit institutions430/8€10k€29k▲
Trade debts44€9k€33k▲
Suppliers440/4€9k€33k▲
Advances received on contracts in progress46€81k€303k▲
Taxes, remuneration and social security45€78k€95k▲
Taxes450/3€51k€60k▲
Remuneration and social security454/9€27k€35k▲
Other amounts payable47/48€4.13M€2.95M▼
Accrued charges and deferred income492/3€20k€18k▼
Income statement
Code20242025
Operating income70/76A-€1.20M
Turnover70-€1.20M
Other operating income74-€2k
Operating charges60/66A-€543k
Services and other goods61-€254k
Remuneration, social security and pensions62€208k€287k▲
Other operating charges640/8€1k€1k▲
Gross operating margin9900€825k-
Operating profit (loss)9901€616k€655k▲
Financial income75/76B€11k€2.03M▲
Recurring financial income75€11k€2.03M▲
Income from current assets751-€2.03M
Other financial income752/9-€50
Financial charges65/66B€317k€394k▲
Recurring financial charges65€317k€394k▲
Debt charges650-€350k
Other financial charges652/9-€44k
Profit (loss) for the period before taxes9903€310k€2.29M▲
Income taxes67/77€76k€66k▼
Taxes670/3-€66k
Profit (loss) for the period9904€234k€2.22M▲
Profit (loss) for the period to be appropriated9905€234k€2.22M▲
Appropriation of the result
Profit (loss) to be appropriated9906€234k€2.22M▲
Transfer to equity691/2€234k€2.22M▲
To other reserves6921€234k€2.22M▲
Social balance
Average headcount (FTE)90873.04.4▲
The notes to these accounts (45 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
10-07
NBB filing
Annual accounts filed
fiscal year 2025 · full schema
2025
31-12
Financial
Highest result since 2019net €2.22M ▲850%
Net result €2.22M, the highest in the series.
27-05
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
31-12
Financial
Equity above €2MEq €2.10M ▲12.6%
6 profitable years in a row build equity to €2.10M.
06-06
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2023
31-12
Financial
Weakest financial yearnet €193k ▼48%
Net result drops to €193k, the lowest in the series; recovery starts the following year.
07-06
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2022
05-07
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2021
31-12
Financial
Equity above €1MEq €1.30M ▲62.3%
3 profitable years in a row build equity to €1.30M.
01-06
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
2020
31-12
Financial
Equity above €500kEq €798k ▲198%
2 profitable years in a row build equity to €798k.
22-06
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
4 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Sint-Truiden · 1 establishment unit since 2018
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
N.B. de Borchgravestraat 44303800 Sint-TruidenGround area
8,192 m²
Building footprint
3,651 m²
Volume, LiDAR
30,089 m³
2 parcels, Flanders · tallest building 23.4 m, ±7 floors. Linked by address, not a title deed.
1 establishment unit
ANTWERP PHARMACIES
since 20182.278.443.490
2 parcels
Flanders
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 71352C0650/00X002 | Flanders | 7,434 m² | 1 · 2,995 m² | 8.1 m · 2 fl. |
| 11803C1904/00G000 | Flanders | 758 m² | 1 · 656 m² | 23.4 m · 7 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1 · via establishment units: 1
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
1 of these parcels carry protected heritage (source: regional heritage registers, Onroerend Erfgoed / patrimoine.brussels).
Public money · subsidies and aid
Flemish government
2025 · 1 entry · 2,000 EUR awarded · 2,000 EUR paid| Year | Entries | awarded | paid |
|---|---|---|---|
| 2025 | 1 | 2,000 EUR | 2,000 EUR |
Schemes
Hinderpremie bij openbare werken
Similar companies · same sector, comparable size
Apotheek Antverpia
BE 0404.751.702
Kontich · Eq €4.33M
PHARMACIE HOUBA
BE 0891.466.622
Brussel · Eq €4.28M
Popelin Apotheken
BE 1004.967.609
Anderlecht · Eq €4.27M
Superphar
BE 0406.879.465
Namur · Eq €4.16M
IMBEFRANCE
BE 0443.801.328
Halle · Eq €4.14M
Of 5,224 companies in sector 47730 we hold annual accounts for 3,863. 1,258 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded08-08-2018
Fiscal year end31-12
Activities, NACEBEL
47730Retail sale of pharmaceutical products
64200Holdings
64210Activities of holding companies
68110Buying and selling of own real estate
68201Renting and operating of own or leased residential real estate, excluding social housing
70200Business and other management consultancy
70220Business consulting
Sources
Crossroads Bank for EnterprisesNational Bank · 7 filingsAddress and cadastre registers
Data from official sources, last processed on 16-09-2026. Scores and ratios are computed by Checked and are not a credit decision.